Colforsin (Forskolin)

For research use only.

Catalog No.S2449 Synonyms: Coleonol, Colforsin

77 publications

Colforsin (Forskolin) Chemical Structure

CAS No. 66575-29-9

Colforsin (Forskolin, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 176 In stock
USD 138 In stock
USD 340 In stock
USD 466 In stock
USD 718 In stock
USD 3767 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Colforsin (Forskolin) has been cited by 77 publications

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Colforsin (Forskolin, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  NX3LNGJySXCxcITvd4l{KEG|c3H5 MXq0NOKh|ryP MY[0POKhcA>? MUDEUXNQ NV\jVXhycW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 M3:xcmFxd3C2b4Ppd{BCe3OjeR?= MWq0NOKh|ryP NF3LSpk1QMLiaB?= MlLWSG1UVw>? NWj5N5U3cW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> M3nuOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HT-29  MVzBdI9xfG:|aYOgRZN{[Xl? NXvRZ2RtPDEEoN88US=> NYLGUGxMPDkEoHi= Mn\3SG1UVw>? NWnZRpFCcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 NFjV[pBCeG:ydH;zbZMhSXO|YYm= NX3ubHBnPDEEoN88US=> MmLoOFjDqGh? NHzCfnBFVVOR M1:3NYlv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> NGPIU2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  NHzZN4RHfW6ldHnvckBCe3OjeR?= MV:0NOKh|ryP MXq3JIQ> M2O5TGROW09? MV;y[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 Mlr1SpVv[3Srb36gRZN{[Xl? M1zUXVQxyqEQvF2= M4XyN|ch\A>? NGHvN|hFVVOR NEfhVIRz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg NFizXGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  M2rxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVO0NOKh|ryP MUSwMVczKGh? NF;aU3VFVVOR MkS3bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jhTVQxyqEQvF2= MW[wMVczKGh? MV;EUXNQ MmLCbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> M4j3W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HT-29  NISxcVZHfW6ldHnvckBCe3OjeR?= M4nYeVQxyqEQvF2= NFHTPIk1QMLiaB?= M1n5d2ROW09? NETsWpFi[3SrdnH0[ZMhWFB{QR?= M3PqRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
SW480 M4frbmZ2dmO2aX;uJGF{e2G7 NIW4Zok1OMLizszN MorFOFjDqGh? NXrHNXJsTE2VTx?= Mn3XZYN1cX[jdHXzJHBROkF? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
C6 MlT1SpVv[3Srb36gRZN{[Xl? M1WwUVExKM7:TdMg Ml7DNlAhdWmw MlnVbY5kemWjc3XzJINCVVBiYXPjeY12dGG2aX;u M1KzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[5OFE4Lz5{NUC2PVQyPzxxYU6=
Huh-7 MkLWSpVv[3Srb36gRZN{[Xl? NFXZR5cxNTJyIN88US=> M3LtbFIhcMLi M3TYR5Jme3WudIOgbY4h[SCmb4PlMYRmeGWwZHXueEBqdmO{ZXHz[UBqdiClLV35Z{BmgHC{ZYPzbY9vKGG2IITo[UBxem:2ZXnuJIFv\CCvUl7BJIxmfmWucx?= NFPuXpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVg{PCd-MkWxNFk5OzR:L3G+
THP-1  NXPofXBuTnWwY4Tpc44hSXO|YYm= NFXhNpIyNzFyIN88US=> M17ne|LDqGh? M3vRbmROW00EoB?= NIDwfVB{fXCycnXzd4V{KE2FUD2xJJBzd2S3Y4Tpc47DqA>? NGn2XYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1OFg5Oid-MkWxOVQ5QDJ:L3G+
BeWo  Mn:3SpVv[3Srb36gRZN{[Xl? NIrKcW4zOCEEtV2= NIHycZQ1QCCq MkDmSG1UV8Li NIj0bI5qdmS3Y3XzJINmdGxiZoXzbY9v NHjKNmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG4OFQ4Pyd-MkWxPFQ1Pzd:L3G+
ventricular cardiomyocytes  NXPBZ45kTnWwY4Tpc44hSXO|YYm= MlnjNE4xOS1zMDFOwG0> NES3fZhmfm:tZYOgZY4hcW6xdILvdIlkKHKnc4DvcpNmKDF{MNMxNVUmKGGkb4\lJIJie2GuIIfpeIgh[W5iRVO1NOKhd2ZiMj6yJOK2VQ>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyM{GxN{c,OjV{MEOxNVM9N2F-
ventricular cardiomyocytes  NIjqbVNHfW6ldHnvckBCe3OjeR?= MnLsNE4xOS1zMDFOwG0> MU\pcoNz\WG|ZYOgJINCVVBiYXPjeY12dGG2aX;u MonQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEOxNVMoRjJ3MkCzNVE{RC:jPh?=
MIN6  MnP1SpVv[3Srb36gRZN{[Xl? MnvrNVAh|ryPwrC= M1\BR|MhcA>? MX\pcoNz\WG|ZYOgSFMhdVKQQTDlfJBz\XO|aX;u NHHwbmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0NVEzPCd-MkWyOFEyOjR:L3G+
L6 NXL3T4pNTnWwY4Tpc44hSXO|YYm= NWfNd4FVPDBiwsXN MV2yOEBp M2rnW4lvcGmkaYTzJGROUDFvaX7keYNm\CCDa4SgZYN1cX[jdHnvci=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ2N{W1NEc,OjV{NEe1OVA9N2F-
HEK‐CFTR M4X0ZWZ2dmO2aX;uJGF{e2G7 M2f5R|LjiJN3MNMg{txO MVWwMVEzKG2rbh?= MmS2SG1UV8Li M3z2cYlv\HWlZYOgZUBld3On4pEQ[IVx\W6mZX70JIlw\GmmZTDl[oZtfXkEoB?= NETHfGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|IxPyd-MkWyOlMzODd:L3G+
SK-N-SH M3LtcWNmdGxiVnnhZoltcXS7IFHzd4F6 M3TsWVExKM7:TdMg MnftOFghcA>? M4LBdIVvcGGwY3XzJHNMNU5vU1igcoV2em:kbHHzeI9u[SClZXzsJJZq[WKrbHn0fS=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  NYnBbZNRTnWwY4Tpc44hSXO|YYm= M4Dqe|ExKM7:TdMg M3fhd|ExNzNyL{[wJI1qdg>? M1exe4lv[3KnYYPld{Bt\X[nbIOgc4YheC4Qsj3jZZRmdmmwIDjz[ZI3PzVrIHHu[EBqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDwMe6zNWOjdHXubY4hMHOnck[3OUkhcW5iKIDldokqdnWlbHXhdkBz\Werb37z NXvVZVdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
SK-N-AS  M2nN[2Z2dmO2aX;uJGF{e2G7 MXqxNEDPxE4EoB?= NWTJVopEOzBibXnu M1vBS4lv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJO6zNWOjdHXubY4hMHOnck[3OUktKHBvR2PLN:6zKCi|ZYK5LUBidmRiY3;uZ49ucXSjboSgbIlocGW{IHzleoVteyCxZjDhZ5RqfmVuIIXudIhwe3Cqb4L5cIF1\WRuIN8yMYNifGWwaX6= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  MkTnSpVv[3Srb36gRZN{[Xl? NVrSb3p3OTBizszNxsA> M{PWdlI1KGh? M{jl[olv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBkgWOuaX6gSFE> MljpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  NU[yU2ZFTnWwY4Tpc44hSXO|YYm= NFm5T4YyOCEQvF5CpC=> NXGyRVM{OjRiaB?= M4rDVolv[3KnYYPld{B1cGViY1HNVEBt\X[nbIRCpC=> NFi0[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1f6fVExKM7:TdMg NFWzS24zPC92ODDo NH\EWo9mdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
granulosa cells MWXGeY5kfGmxbjDBd5NigQ>? NYi1cZpOOTBizszN MljYNlQhcA>? M4XvcYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUGwOUc,OjV|M{mxNFU9N2F-
granulosa cells M37hc2Z2dmO2aX;uJGF{e2G7 MoLmNVAh|ryP M{m1d|I1KGh? NGK0Vm5qdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 NVP1WXF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|kyODVpPkK1N|M6OTB3PD;hQi=>
granulosa cells NETVW|RHfW6ldHnvckBCe3OjeR?= NF\6VlEyOCEQvF2= NH3DW2syOi9{NDDo NVzvRmVFcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdoVxd3K2ZYKgZYN1cX[rdImg[o9zKHSqZTDsc45o\XO2IH\yZYdu\W62IDlijLI5PTRxK{G4VmdUOi6OVVOp Mnf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{mxNFUoRjJ3M{O5NVA2RC:jPh?=
granulosa cells M{DTfmZ2dmO2aX;uJGF{e2G7 NYK1RYhIOTBizszN M3fQNFEzNzJ2IHi= MUnpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\sLiUlfTNuKhdVKQQR?= NInL[|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVExPSd-MkWzN|kyODV:L3G+
BeWo  M3vqUWZ2dmO2aX;uJGF{e2G7 MVuyNOKhyrWP MonmOFjDqGkEoB?= M4HZV2ROW00EoB?= Mlzp[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gS2NONTF? NV;kUJFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlIzPjBpPkK1N|YzOjZyPD;hQi=>
BeWo  NHjF[5JHfW6ldHnvckBCe3OjeR?= M{i3UVIxyqEEtV2= M3i0U|Q5yqCqwrC= NGfkeJhFVVORwrC= NFLkV5hld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 NInn[WQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NlI3OCd-MkWzOlIzPjB:L3G+
BeWo  MUTGeY5kfGmxbjDBd5NigQ>? MUKyNOKhyrWP NYrafZNUPDkEoHlCpC=> M4G3d2ROW00EoB?= NWLzcZlzcW6lcnXhd4V{KHSqZTDi[ZRiNWiFRzDy[Yxm[XOn NEXjToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NlI3OCd-MkWzOlIzPjB:L3G+
EM1  M3zZ[mZ2dmO2aX;uJGF{e2G7 MnrGNVXjiIsQvF2= MkKxOFghcA>? MVfy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:owrDMTWbDqG:{wrDQWGdUOsLiaX9CpGNCVFJvIH;yxsBGWEGFMj3zbYxmdmOnZDDFUVEh[2WubIRCpC=> NGnvTpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3PFY3OSd-MkWzO|g3PjF:L3G+
Primary bovine chondrocytes NVvlSZIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTNeGg2|ryP M{[3SVQ5KGh? NIH6cldz\X[ncoPld{B1cGViaX7obYJqfG:{eTDl[oZm[3Rib3[gZ4Vt\WOxeHniJI9vKHC{b3zp[oVz[XSrb36gbY4h\3Kxd4ToJJBt[XSnIHPoc45lem:leYTldy=> NF22fG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwOlAyPid-MkW0NFYxOTZ:L3G+
RBMECs NFvBcWtHfW6ldHnvckBCe3OjeR?= MkOyOeKh|ryP M2j4cVEhcA>? MmfsZoxw[2u|IITo[UBi[3SrbjDjfZRwe2unbHX0c44hemWjcoLhcodmdWWwdDDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboVCpC=> NEf5[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NICxcXBHfW6ldHnvckBCe3OjeR?= MmHhOeKh|ryP M3PoelEhcA>? NXHRepBw[myxY3vzJJRp\SCHTVHQMWlKNWmwZIXj[YQh[2ijbnflJIlvKE2OQzDwbI9{eGixconsZZRqd25? NV3oR2VkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs MoT0SpVv[3Srb36gRZN{[Xl? M1rRU|XDqM7:TR?= MmXXNUBp Mnr4doV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 NYTBVYtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs MUXGeY5kfGmxbjDBd5NigQ>? M4PaWVXDqM7:TR?= NITWSZQyKGh? NXO5R4p[cW6qaXLpeJMhfGinIHTlZ5Jm[XOnZDDv[kBidW:3boSgc4YhYk9vMTDpckBOTnNiaX7keYNm\CCkeTDFUWFRNUmL NEn2PYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs MkXTSpVv[3Srb36gRZN{[Xl? NVfmUVg3PcLizszN MVqxJIg> NWLiPI82eHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJGhTWCCobIX4JIFkem:|czD0bIUhSlSEIHnu[JVk\WRiYomgJGVOSVBvSVm= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs NV3OS3I4TnWwY4Tpc44hSXO|YYm= NW\B[VhnPcLizszN NGXYZ5EyKGh? MYHwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> M2nzT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs M2X3emZ2dmO2aX;uJGF{e2G7 M{Wyb|XDqM7:TR?= MonFNUBp MmrnZoxw[2u|IITo[UBi[3SrdnH0bY9vKG:oIGLoc2EwWk:FSzDpcoR2[2WmIHL5JGVOSVBvSVm= NXzmR|JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs M{fE[2Z2dmO2aX;uJGF{e2G7 MlW0NE4xPS9yLkWvOUDPxE1? M3XoflAvOjViaB?= NV7Kfo0ycW6lcnXhd4V{KGODTWCgZ49v[2WwdILheIlwdg>? M{i1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
ThGCs  NUX1V5hnTnWwY4Tpc44hSXO|YYm= M3vrSlEx6oDMzszN M1GyV|MhcA>? NWGxUXJPcW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= NFzPS|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzN|AzPyd-MkW0N|MxOjd:L3G+
ThGCs  MW\GeY5kfGmxbjDBd5NigQ>? Mkn3NVDjiIsQvF2= NGjURYY16oDMaB?= M17EOIlv[3KnYYPld{BEd0OuMj3pcoR2[2WmIFXEUlLDqGenbnWg[ZhxemW|c3nvci=> M{fEfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOzNFI4Lz5{NUSzN|AzPzxxYU6=
ThGCs  MYXGeY5kfGmxbjDBd5NigQ>? NGPBVYcyOOLCit88US=> MX:05qCLcA>? NITQXINifWevZX70d{BJUUZzQTDs[ZZmdHNidHjheEB4\XKnIIP0bY12dGG2ZXSgZpkhS2:FbEK= NYDob|V3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
LNCaP  NWPSc2t6TnWwY4Tpc44hSXO|YYm= MnjJNVDDqM7:TR?= MWCxNkBpyqB? MU\EUXNQ NUmzNYdTcW6mdXPld{BiKGS{YX3heIlkKGmwY4LlZZNmKG:oIFPSSWIyKGGldHn2bZR6 MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV2OEC5PUc,OjV3NEiwPVk9N2F-
BeWo M2XR[WZ2dmO2aX;uJGF{e2G7 NFPQbpMzOMLiwsXN NI\odFA1QMLiaB?= NEe0fZZFVVOR M4OzRolv[3KnYYPld{B1cGViYXTo[ZNqd25ib3[gWGhRNTFibX;uc4N6fGW| NXrzWlVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlY4PDBpPkK1OVY3PzRyPD;hQi=>
BeWo MniySpVv[3Srb36gRZN{[Xl? MlPQNlDDqML3TR?= M2nsUlQ5yqCq NUPTN3VSTE2VTx?= NYDCfpNxcW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> M3X3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[2O|QxLz5{NUW2Olc1ODxxYU6=
OCI-Ly18  NUnIXYtmTnWwY4Tpc44hSXO|YYm= MWq0NOKh|ryP MoDnNeKhcMLi MVLEUXNQ NYfV[25wcW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM> NGX1VHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlIzOCd-MkW1O|YzOjB:L3G+
OCI-Ly1  NUi2ZWNRTnWwY4Tpc44hSXO|YYm= NUXzXpFDPDEEoN88US=> MXyxxsBpyqB? MWHEUXNQ Mk\SbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= M3W5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2NlIxLz5{NUW3OlIzODxxYU6=
3T3-L1 MkHzSpVv[3Srb36gRZN{[Xl? M2\XOlIvPS93IN88US=> NHrKWYMzPCCqwrC= MkD3d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? M3\icVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwOVk4Lz5{NUW5NFU6PzxxYU6=
HEK293  NH\senpHfW6ldHnvckBCe3OjeR?= NIK2NWc26oDLwsXN MVmzNEBucW5? Mkf1bY5kemWjc3XzJINCVVBibHX2[Yx{ NXO4Z5hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVE6ODhpPkK1OVkyQTB6PD;hQi=>
hADSCs MVvGeY5kfGmxbjDBd5NigQ>? M160NlXjiIoEtV2= NFLKUFk{OCCvaX6= M3PVc4lv[3KnYYPld{BkSU2SIHzleoVtew>? M2HXdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmxPVA5Lz5{NUW5NVkxQDxxYU6=
SH-SY5Y  M{\yNWZ2dmO2aX;uJGF{e2G7 NHLGPVcyOMLizszN NGHmOYEyyqCqwrC= M{HQVYlv[3KnYYPld{BCT0NzIH3SUmEhdGW4ZXy= M4jlNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm3OFM{Lz5{NUW5O|Q{OzxxYU6=
SH-SY5Y  NUPO[mI5TnWwY4Tpc44hSXO|YYm= MV2xNOKh|ryP M2r4[|HDqGkEoB?= NGTuVGdqdmO{ZXHz[ZMhVFWFIHHjeIl3cXS7 M4[0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm3OFM{Lz5{NUW5O|Q{OzxxYU6=
UACC-647  NWG3TplCTnWwY4Tpc44hSXO|YYm= NEXVUXEyOMLizszN Ml23NVUhdWmw Mk\2SG1UVw>? M2\Bcolv[3KnYYPld{BmTUZ{IIDoc5NxcG:{eXzheIlwdiCuZY\lcJPDqA>? MlH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEOwNlUoRjJ3N{CzNFI2RC:jPh?=
UACC-647  NEDlWphHfW6ldHnvckBCe3OjeR?= NEfJcFgyOMLizszN MnPtNVUhdWmw NViyZ4hSTE2VTx?= NVrrVXJKcW6qaXLpeJMhTVKNIIDoc5NxcG:{eXzheIlwdg>? NIT6WW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN|AzPSd-MkW3NFMxOjV:L3G+
UACC-647  MWjGeY5kfGmxbjDBd5NigQ>? NUTXNWFtTE2VTx?= M3XNe4xm[WS|IITvJIEhemm|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN|nDqM7:TTm= M2fldFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNFI2Lz5{NUewN|AzPTxxYU6=
SC M1P6fmZ2dmO2aX;uJGF{e2G7 MYiwMlUh|ryP MX[3NkBp NWTrZ21VcW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyNUi3OEc,OjV5MEW4O|Q9N2F-
SC M1;3N2Z2dmO2aX;uJGF{e2G7 MUWwMlUh|ryP M2Loe|I1KGh? NV;3R4dzdWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= Mm\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEW4O|QoRjJ3N{C1PFc1RC:jPh?=
oocytes NVPlXoVWTnWwY4Tpc44hSXO|YYm= MkH4OUDPxE1? MkLjNlQhcA>? MXXheJRmdnWjdHXzJJJpNWmwc4XsbY4h[WO2aX;uJI9vKG:xY4n0[UBIXkKGIIPp[45q\mmlYX70cJnDqA>? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyN{i1OEc,OjV5MEe4OVQ9N2F-
BeWo MV3GeY5kfGmxbjDBd5NigQ>? MXSxNQKBks7:TdMg M{LD[lczKGh? MVLEUXNQ M2XLSY1m\GmjdHXzJGJmX29iY3XscEBlcW[oZYLlcpRq[XSrb36= NHL5O4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexN|QzPSd-MkW3NVM1OjV:L3G+
GH3 MWPGeY5kfGmxbjDBd5NigQ>? NEC5SZQyyqEQvF2= M33xR|YucA>? M{ezO4lv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u NGH6e4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO|AyQCd-MkW3NlcxOTh:L3G+
GH3 MmC1SpVv[3Srb36gRZN{[Xl? M2PIfFHDqM7:TR?= M1;0U|YucA>? NX3ab3kz[XS2ZX71ZZRmeyC2aHWgZ49zemWuYYTpc44h[mW2d3XlckBRWkxiYX7kJGJu[WxzIHX4dJJme3Orb36= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{CxPEc,OjV5MkewNVg9N2F-
PC12 MlL1SpVv[3Srb36gRZN{[Xl? MWOyOeKh|ryP MorPOFghcA>? MlHUZYN1cX[jdHXzJINCVVB? Mlq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkmzNFUoRjJ3N{[5N|A2RC:jPh?=
BAECs M3fnemZ2dmO2aX;uJGF{e2G7 M3GwfFI2KM7:TR?= M4jRXVI1KGh? NWLLdY44\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7OEiyOkc,OjV5OUi4NlY9N2F-
GLUTag  M4DyZ2Z2dmO2aX;uJGF{e2G7 MonBNVDjiIoEtV2= NXfZd5VoPCCq MYDpcoNz\WG|ZYOgeIhmKHCFUlXCJIxmfmWuczD3bZRpKHSqZTDJRm1Z M{\3O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
GLUTag  MkXxSpVv[3Srb36gRZN{[Xl? MlvnNVDjiIoEtV2= NUXUTYJ2OC9{L{SgbC=> NGroSJp{fGmvdXzheIV{KEeOUD2xJJNm[3KndHnvckBkd3S{ZXH0[YQhf2m2aDDJRm1Z NX:3O2Q2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N|I3OzFpPkK1PFMzPjNzPD;hQi=>
PBMC NVjpRpBVTnWwY4Tpc44hSXO|YYm= MUS1NOKh|ryP MUiyOOKhcMLi MWHpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG MkDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6Nk[wO|koRjJ3OE[2NFc6RC:jPh?=
H295R  MXHGeY5kfGmxbjDBd5NigQ>? M4[ySFExyqEQvF2= MUW0POKhcA>? NV;odmxxcW6lcnXhd4V{KHO2ZYLvbYQhdWW2YXLvcIl1\XNiaX6geIhmKGGwZILv[4VvNCCvaX7ldoFtdy1iYX7kJIdtfWOxY3;yeIlkd2mmIIDheIh4[Xm| MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUW1Okc,OjV6Nkm1OVY9N2F-
3T3-L1 preadipocytes M3z4WWZ2dmO2aX;uJGF{e2G7 NWLmOFVMOTBizszNxsA> MWWxNkBp Ml\JbY5lfWOnczDDVmVDKHCqb4PwbI9zgWyjdHnvckBidmRiQz;FRnDPuiCneIDy[ZN{cW:w NELpSFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmyPFA2QCd-MkW5NlgxPTh:L3G+
PCCL3 MormSpVv[3Srb36gRZN{[Xl? NWj2PFJLOTBiwsXN MUKyOEBp NHzFVXdmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= NFvXVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NFk2Pid-MkW5OlA6PTZ:L3G+
SCG M4TmXWZ2dmO2aX;uJGF{e2G7 MUSxNFAh|ryPwrC= MVrEUXNQ MW\y[YR2[2W|IITo[UBmgGOrdHHibYxqfHlib3[gV2NIKG6ndYLvcpM> NEnEdWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NlE{Oid-MkW5OlIyOzJ:L3G+
HEK-293 M1ToVmZ2dmO2aX;uJGF{e2G7 NWPKfXVDOzVizszNxsA> Ml7sSG1UVw>? NUfjWGJDcW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> NVfLeoxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlIyOzJpPkK1PVYzOTN{PD;hQi=>
SCG NWexbmVWTnWwY4Tpc44hSXO|YYm= NUPOVoJPOjBizszNxsA> NH\tNYlFVVOR MUTy[ZZmenOrYnz5JJN2eHC{ZYPz[ZMhUUuYIIfpeIgh[SCLQ{WwJI9nKDJ2LkSg{txO MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MkGzNkc,OjV7NkKxN|I9N2F-
PC-3 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{HTNlQxKML3TR?= NVGxZlVQOjRxNEivO|IhcA>? MlXTSG1UVw>? M1TFOIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD0bY1mKGSncHXu[IVvfGy7 M3z5W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzPFM3Lz5{NkCyN|g{PjxxYU6=
PC-3 NYPKZ|VoTnWwY4Tpc44hSXO|YYm= NFLNS4k1OCEEtV2= NGnCUGIzKGh? MV3EUXNQ MVvs[YFleyC2bzDQVFJCKGGldHn2ZZRqd25? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{izOkc,OjZyMkO4N|Y9N2F-
SH-SY5Y MoTLSpVv[3Srb36gRZN{[Xl? M1HDUVMxKM7:TR?= NGHGeVA{OCCvaX6= MVfEUXNQ MkK1d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIFkfGm4YYTpc44hd2ZiUFvB NUTTW3ZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlUyOzdpPkK2NFI2OTN5PD;hQi=>
EndoC-βH1 MVXGeY5kfGmxbjDBd5NigQ>? NEXtWYY2yqEQvF2= Mkm1NUBp NGnrb4Zt\WGmczD0c{BiKHO2cn;u[{BkSU2SIHnuZ5Jm[XOn M2\CUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEK4OVYzLz5{NkCyPFU3OjxxYU6=
EndoC-βH1 NYDwNHk6TnWwY4Tpc44hSXO|YYm= M1\jc|XDqM7:TR?= NYTG[VVzOSCq NEf1dGJxd3SnboTpZZRmeyCpbIXjc5NmNWmwZIXj[YQhcW6|dXzpckB{\WO{ZYTpc44hcW5idHjlJJBz\XOnbnPlJI9nKGeudXPvd4U> NYLUcHlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlg2PjJpPkK2NFI5PTZ{PD;hQi=>
RBMECs MkPXSpVv[3Srb36gRZN{[Xl? NVH1coFvPcLizszN NXrCRVBROSCq NI\FWVNqdmirYnn0d{BGVUGSLVnJMYlv\HWlZXSgbY5i[3SrdnH0bY9vKG:oIGLhdFHDqA>? NELlO4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0OFY3Oyd-Mk[wOFQ3PjN:L3G+
AML-12  MkXRSpVv[3Srb36gRZN{[Xl? MXeyNEDPxE1? M{fweFMhcA>? M4LwPYlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? M3ToclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES4PVg2Lz5{NkC0PFk5PTxxYU6=
AML-12  MmKySpVv[3Srb36gRZN{[Xl? NILhe2szOCEQvF2= NFXFWJI{KGh? M37Lc5VxNXKnZ4XsZZRme8LiUHfjNYEtyqCSZYDjb{wh[W6mwrDHOpBkyqCvUl7BJIxmfmWucx?= MoHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  MmPtSpVv[3Srb36gRZN{[Xl? NU\nRldpOjBizszN M13XeFEuQCCq MnLKbY5kemWjc3XzJIdtfWOxc3WgdJJw\HWldHnvci=> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OEm4OUc,OjZyNEi5PFU9N2F-
AML-12  MnjXSpVv[3Srb36gRZN{[Xl? NHqwZmIzOCEQvF2= MXOzJIg> NYXFbXQ4fXC{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNiYYSgWIhzNTRzMTDhcoQhW2W{LUS5Ny=> NV60NVlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFg6QDVpPkK2NFQ5QTh3PD;hQi=>
Caco-2  MYnGeY5kfGmxbjDBd5NigQ>? M3;3TlAvOS9zL{GwJO69VQ>? MmHZNlQhcA>? MU\pcoNz\WG|ZYOgUXJROiCycn;0[YlvKGyndnXs NFXuc3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PVExOid-Mk[wOFkyODJ:L3G+
Caco-2  Ml\RSpVv[3Srb36gRZN{[Xl? M3HZS|AvOS9zL{GwJO69VQ>? NXns[nN5OjEEoH3pci=> NYLBXnVpcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ2FOWCCuZY\lcJM> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OUGwNkc,OjZyNEmxNFI9N2F-
bovine oocytes NEDYTIFHfW6ldHnvckBCe3OjeR?= Mlu4NVAxyqEQvF2= NFvtXIMyOsLiaB?= M2DIeolvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiTmDQRUBidmRxb4KgUnBRSyC2bzDzeIlufWyjdHWgdoV{fW2ydHnvckBw\iCvZXnvd4l{ M1fpWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEWxOlEyLz5{NkC1NVYyOTxxYU6=
BeWo  NXHhbZh1TnWwY4Tpc44hSXO|YYm= MVSyOgKBkc7:TR?= NYTQUoE2OjRxNEivO|IhcA>? MkLYcIVi\HNidH:gZY4hcW6lcnXhd4UhcW5idHjlJIV5eHKnc4Ppc44hd2Zib4To[ZIh\nW|aX;uJI1iemuncoO= NX;DVIRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVM2PDlpPkK2NFU{PTR7PD;hQi=>
Spinal cords  M2\kOmZ2dmO2aX;uJGF{e2G7 NHnZfmMyyqEQvF2= MoHRN|AhdWmw M3jXVpN1cW23bHH0[ZMh[0GPUDDs[ZZmdHN? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NkmyOkc,OjZzMk[5NlY9N2F-
MDCK  M{exOmZ2dmO2aX;uJGF{e2G7 NY\Wb4JyOTBiwsXN Ml3CNlQhcA>? NYnnbXJJTE2VTx?= Mon3bY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy M4HBWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkCyN|UzLz5{NkKwNlM2OjxxYU6=
MDCK  Mnu0SpVv[3Srb36gRZN{[Xl? MWixNEDDvU1? MXSyOEBp M2XDW2ROW09? M1m1PZVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKFSJRj5OtlEh[W6mIFPUS2bDqA>? NWnsWJpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
RPMI 8226 NWjvPZZ5S2WubDDWbYFjcWyrdImgRZN{[Xl? MoLBNE0yODBizszN Mlv6O|LjiImq MYDpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
H929 M3fQVGNmdGxiVnnhZoltcXS7IFHzd4F6 MnXWNE0yODBizszN MorzO|LjiImq M{jsXIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NIXhZpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
U266 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\He|AuOTByIN88US=> NFS4[3g4OuLCiXi= MXTpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MnTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
OPM-2 NWDUbGxyS2WubDDWbYFjcWyrdImgRZN{[Xl? NIfrOVkxNTFyMDFOwG0> NFHmOFc4OuLCiXi= MUXpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
INA-6 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mnq3NE0yODBizszN M1LPUlcz6oDLaB?= MUTpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= M3fPXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
RBMECs  NIHS[|FHfW6ldHnvckBCe3OjeR?= NITkT5g2yqEQvF2= NFnSOGsyyqCq NF\ZNpVjdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? NEH2[nk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1PFA{QSd-Mk[zOVgxOzl:L3G+
Mo-DCs MWPGeY5kfGmxbjDBd5NigQ>? MmrOOVAh|ryP MlXTNlTjiImq NVmwVpBweHKxbX;0[ZMhUUxvMkOgdJJw\HWldHnvckBqdiC2aHWgd5Vx\XKwYYThcpQhd2Zieontc5NidiC|dHnteYxifGWmIF3vMWREe8Li M1\rXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEGyPVQ5Lz5{NkSxNlk1QDxxYU6=
HEK293 NX3rWZpuTnWwY4Tpc44hSXO|YYm= NGXvRnoyOCEQvF2= M{nxU|YhcA>? M1XH[4lv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4Yhd3[ncnX4dJJme3OnZDDLUGhNOyCjdDDTOFM{ MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR|NUS5PEc,OjZ2M{W0PVg9N2F-
ASK NGXnWm5HfW6ldHnvckBie3OjeR?= Mnj0NUBpeg>? NI\mNYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES5OlQyLz5{OES5OlQyRC:jPh?=
Vero E6 MUjBcpRqfmm{YXygZZN{[Xl? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ4M{WzPUc,OTd4NkO1N|k9N2F-
epithelial cells NXLwVGNuTnWwY4Tpc44h[XO|YYm= MWGxJJVO M2nL[lQtKDZuIHHu[EA5KGSjeYO= MnLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O|g6RC:jPh?=
HepG2 (DPX-2) MXHGeY5kfGmxbjDhd5NigQ>? NHHXWVIzPCCqcoO= NVz1S4R{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OlYxPDNpPkKwPVY3ODR|PD;hQi=>
HepG2 NUnUZolETnWwY4Tpc44h[XO|YYm= NWLGV|JQOjRiaILz NULjSJB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OlYxPDNpPkKwPVY3ODR|PD;hQi=>
HepG2 (DPX-2) MUHGeY5kfGmxbjDhd5NigQ>? MlPzNlQhcHK| MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HEK293T MYfGeY5kfGmxbjDhd5NigQ>? NF31Z5oyOCC3TR?= Ml;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEezNlUoRjJ2M{i3N|I2RC:jPh?=
HEK293 NX75NGpxTnWwY4Tpc44h[XO|YYm= MXexNEB2VQ>? MnfCNVYhcHK| M{PWcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEO1OVEzLz5{NkSzOVUyOjxxYU6=
MCF7 NFv4eYtEgXSxdH;4bYNqfHliYYPzZZk> NIC2e5M1QCCqcoO= M3PBOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEO4OlkzLz5{OEizPFY6OjxxYU6=
HEK293 MkjCSpVv[3Srb36gZZN{[Xl? MkXwN|AhdWmwcx?= NYP5NnVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPzZpPkOwNFA3OTd4PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

Protocol

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol '37 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
Synonyms Coleonol, Colforsin
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

cAMP Signaling Pathway Map

Tags: buy Colforsin (Forskolin) | Colforsin (Forskolin) supplier | purchase Colforsin (Forskolin) | Colforsin (Forskolin) cost | Colforsin (Forskolin) manufacturer | order Colforsin (Forskolin) | Colforsin (Forskolin) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID